Protein Research
Discovery and characterisation of BSP proteins, from expression to cell-based assays.
About protein researchPreclinical protein research
Targeting cancer. Sparing healthy cells.
Assisi Care is developing BSP proteins, a research-stage approach designed to act selectively against cancer cells while sparing normal cells. We pair the science with rigorous data analysis and strategic planning.
Research stage · Not approved for clinical use
The problem
Many cancer treatments can’t tell friend from foe
01
Collateral damage
Conventional chemotherapy attacks rapidly dividing cells, whether they are cancerous or healthy.
02
Limits on treatment
Side effects on healthy tissue often limit how much treatment a patient can receive.
03
A need for selectivity
Therapies that reliably distinguish cancer cells from normal cells could change that balance.
Our approach
The BSP protein platform
Our research asks a focused question: can a protein act against cancer cells while leaving normal cells unharmed?
-
BSP proteins
We design and study BSP proteins, a family of engineered proteins at the centre of our research.
-
Selective recognition
In laboratory studies, BSP proteins are designed to act on features that distinguish cancer cells from normal cells.
-
Cancer cells affected, normal cells spared
Our preclinical work measures cancer-cell death alongside the viability of healthy cells, the balance that matters most.
Early evidence
What our preclinical studies show so far
[XX]%
Reduction in cancer-cell viability in vitro
Placeholder data
[X]
Cancer cell lines tested
Placeholder data
[XX]%
Normal-cell viability retained under the same conditions
Placeholder dataResults are from early laboratory studies and do not show safety or effectiveness in people. Replace each figure with verified data and link it to its source.
What we do
Science, data and strategy under one roof
Data Analysis
Statistics, bioinformatics and clear visualisation that turn raw assay data into decisions.
About data analysisStrategic Planning
R&D roadmaps, target prioritisation and planning for grants, partners and investors.
About strategic planningWhere we are
Development pipeline
Bringing a new therapy to patients takes many careful steps. This is where our BSP program stands today.
-
Discovery
BSP protein candidates identified
-
In vitro validation Now
Selectivity tested in cell models
-
In vivo studies
Efficacy and safety in animal models
-
IND-enabling
Manufacturing, toxicology, regulatory package
-
Clinical trials
First studies in people
Placeholder: confirm the current stage
Our people
Led by scientists
Founder Name
Founder & Chief Scientific Officer
Placeholder bio: degrees, research background and focus.
Team Member Name
Head of Data Science
Placeholder bio: expertise in statistics and bioinformatics.
Advisor Name
Scientific Advisor
Placeholder bio: institution and relevant experience.
Collaborators & support
- Partner logo
- Institution logo
- Grant / funder logo
- Program logo
News & insights
Latest from Assisi Care
Assisi Care launches its new website
Placeholder post. Introduce the company, its mission and the BSP protein program in a few short paragraphs.
Presenting preclinical BSP results at a research conference
Placeholder post. Name the conference, the poster or talk title, and link to the abstract once it is public.
Why selectivity matters in cancer research
Placeholder post. A plain-language explainer on how targeting cancer cells while sparing healthy ones could change treatment.
Collaborate with us to advance selective cancer therapy
We work with research groups, industry partners and investors who share our focus on selectivity.